Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Gilead Sciences completes acquisition of YM BioSciences



           Gilead Sciences completes acquisition of YM BioSciences

PR Newswire

FOSTER CITY, CA, Feb. 8, 2013

FOSTER CITY, CA, Feb. 8, 2013 /PRNewswire/ - Gilead Sciences, Inc. (Nasdaq:
GILD) today announced that it has completed its acquisition of YM BioSciences
Inc. (NYSE MKT: YMI, TSX: YM).

On February 8, 2013,  a subsidiary of Gilead  acquired all of the  outstanding 
common shares of  YM pursuant  to the  terms of a  plan of  arrangement. As  a 
result,  YM  has  become  a  wholly-owned  subsidiary  of  Gilead  and  it  is 
anticipated that the common shares of YM will no longer be listed for  trading 
on the NYSE MKT LLC  or the Toronto Stock Exchange,  on or about February  12, 
2013. Shareholders of YM on this date  will be entitled to receive U.S.  $2.95 
per common share in cash,  and holders of warrants  and stock options will  be 
entitled to receive a cash payment equal to the difference between U.S.  $2.95 
and the exercise price of such warrant or stock option.

About Gilead Sciences
Gilead Sciences is  a biopharmaceutical company  that discovers, develops  and 
commercializes  innovative  therapeutics  in  areas  of  unmet  medical  need. 
Gilead's  mission  is  to  advance   the  care  of  patients  suffering   from 
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North America, Europe and Asia Pacific.

Forward-Looking Statements
This press release includes forward-looking  statements within the meaning  of 
the Private  Securities Litigation  Reform Act  of 1995  that are  subject  to 
risks, uncertainties and other factors, including risks related to the ability
of Gilead  to  advance  YM's  product  pipeline,  including  CYT387,  and  the 
possibility of unfavorable results of clinical trials of CYT387. These  risks, 
uncertainties  and  other  factors  could  cause  actual  results  to   differ 
materially from  those  referred to  in  the forward-looking  statements.  The 
reader is cautioned not to rely on these forward-looking statements. These and
other risks are described in detail in Gilead's Quarterly Report on Form  10-Q 
for the quarter ended  September 30, 2012, as  filed with the U.S.  Securities 
and  Exchange  Commission.  All   forward-looking  statements  are  based   on 
information currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company's website at
  www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead
             Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

SOURCE YM BioSciences Inc.

Contact:

Patrick O'Brien, Investors
(650) 522-1936

Nathan Kaiser, Media
(650) 522-1853
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement